The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
Open accessAbstract
BACKGROUND: Advances in treatments for cystic fibrosis (CF) continue to extend survival. An updated estimate of survival is needed for better prognostication and to anticipate evolving adult care needs. OBJECTIVE: To characterize trends in CF survival between 2000 and 2010 and to project survival for children born and diagnosed with the disease in 2010. DESIGN: Registry-based study. SETTING: 110 Cystic Fibrosis Foundation-accredited care centers in the United States. PATIENTS: All patients represented in the Cystic Fibrosis Foundation Patient Registry (CFFPR) between 2000 and 2010. MEASUREMENTS: Survival was modeled with respect to age, age at diagnosis, gender, race or ethnicity, F508del mutation status, and symptoms at diagnosis. RESULTS: Between 2000 and 2010, the number of patients in the CFFPR increased from 21,000 to 26,000, median age increased from 14.3 to 16.7 years, and adjusted mortality decreased by 1.8% per year (95% CI, 0.5% to 2.7%). Males had a 19% (CI, 13% to 24%) lower adjusted risk for death than females. Median survival of children born and diagnosed with CF in 2010 is projected to be 37 years (CI, 35 to 39 years) for females and 40 years (CI, 39 to 42 years) for males if mortality remains at 2010 levels and more than 50 years if mortality continues to decrease at the rate observed between 2000 and 2010. LIMITATIONS: The CFFPR does not include all patients with CF in the United States, and loss to follow-up and missing data were observed. Additional analyses to address these limitations suggest that the survival projections are conservative. CONCLUSION: Children born and diagnosed with CF in the United States in 2010 are expected to live longer than those born earlier. This has important implications for prognostic discussions and suggests that the health care system should anticipate greater numbers of adults with CF. PRIMARY FUNDING SOURCE: Cystic Fibrosis Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,094
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
Self-citationEmerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., & Gibson, R. L. (2002) · Pediatric Pulmonology · doi:10.1002/ppul.10127 · Cited by 1,007
The changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Stallings, V. A., Stark, L. J., Robinson, K. A., Feranchak, A. P., & Quinton, H. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.02.020 · Cited by 732
Self-citationClinical Care Guidelines for Cystic Fibrosis–Related Diabetes
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1768 · Cited by 726
Self-citationCYSTIC FIBROSIS: GENOTYPIC AND PHENOTYPIC VARIATIONS
Zielenski, J., & Tsui, L.-C. (1995) · Annual Review of Genetics · doi:10.1146/annurev.ge.29.120195.004021 · Cited by 631
Cystic fibrosis mortality and survival in the UK: 1947–2003
Dodge, J. A., Lewis, P. A., Stanton, M., & Wilsher, J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00099506 · Cited by 627
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Konstan, M. W., Morgan, W. J., Butler, S. M., Pasta, D. J., Craib, M. L., Silva, S. J., Stokes, D. C., Wohl, M. E. B., Wagener, J. S., Regelmann, W. E., et al. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.03.006 · Cited by 438
Cited by
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Cystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
Self-citationFuture trends in cystic fibrosis demography in 34 European countries
Burgel, P.-R., Bellis, G., Olesen, H. V., Viviani, L., Zolin, A., Blasi, F., & Elborn, J. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00196314 · Cited by 282
Stephenson, A. L., Sykes, J., Stanojevic, S., Quon, B. S., Marshall, B. C., Petren, K., Ostrenga, J., Fink, A. K., Elbert, A., & Goss, C. H. (2017) · Annals of Internal Medicine · doi:10.7326/m16-0858 · Cited by 192
Self-citationLechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2172oc · Cited by 127
Self-citationSanders, D. B., & Fink, A. K. (2016) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2016.04.001 · Cited by 109
Ramos, K. J., Quon, B. S., Heltshe, S. L., Mayer-Hamblett, N., Lease, E. D., Aitken, M. L., Weiss, N. S., & Goss, C. H. (2017) · Chest · doi:10.1016/j.chest.2017.01.019 · Cited by 95
Self-citationCFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
Balfour-Lynn, I. M., & King, J. A. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.05.002 · Cited by 85
Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis
Haque, A. K. M. A., Dewerth, A., Antony, J. S., Riethmüller, J., Schweizer, G. R., Weinmann, P., Latifi, N., Yasar, H., Pedemonte, N., Sondo, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34960-0 · Cited by 80
Prognostication and risk factors for cystic fibrosis via automated machine learning
Alaa, A. M., & van der Schaar, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-29523-2 · Cited by 80
A 3-year prognostic score for adults with cystic fibrosis
Nkam, L., Lambert, J., Latouche, A., Bellis, G., Burgel, P., & Hocine, M. N. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.03.004 · Cited by 59
Lung transplantation for cystic fibrosis
Morrell, M. R., & Pilewski, J. M. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.11.008 · Cited by 56
Hoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
Franck Thompson, E., Watson, D., Benoit, C. M., Landvik, S., & McNamara, J. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.010 · Cited by 26
Kumar, S., Soldatos, G., Ranasinha, S., Teede, H., & Pallin, M. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.07.013 · Cited by 24
Deaths Related to Bronchial Arterial Embolization in Patients With Cystic Fibrosis
Town, J. A., Monroe, E. J., & Aitken, M. L. (2016) · Chest · doi:10.1016/j.chest.2016.03.009 · Cited by 17
Metadata
- Authors
- MacKenzie, T., Gifford, A. H., Sabadosa, K. A., Quinton, H. B., Knapp, E. A., Goss, C. H., & Marshall, B. C.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-08-19
- Volume
- 161
- Issue
- 4
- Pages
- 233-241
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1991980138
- Cited by
- 355
- References
- 40
- FWCI
- 31.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.